Role of drug ( dexmedetomidine) in controlling the intubation response.

Evaluation Of Nebulized Dexmedetomidine As a premedication In Blunting Hemodynamic Response To Intubation

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/07/014837

Enrollment

100

Registered

2018-07-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- controlled diabetics, normal patients, male and female , 18-60 years of age. Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Evaluation of Nebulized Dexmedetomidine as a premedication In blunting hemodynamic response to intubation: Laryngoscopy and tracheal intubation are noxious stimuli associated with a tra

Eligibility

Inclusion criteria

Inclusion criteria: 1) ASA I ,II 2) Age group 18- 60 yrs 3) male/female 4) patients with normal airway parameters. 5) Patients posted for elective surgeries under general anaesthesia with endotracheal intubation

Exclusion criteria

Exclusion criteria: 1) ASA III,IV,V,VI. 2) patients with anticipated difficult intubation or difficult mask ventilation. 3) Patients with uncontrolled hypertension, cardiac disorders where haeodynamic responses to intubation may be not be tolerated . 4) Patients with poor pulmonary reserve where early desaturation is expected. 5) patients with active secreting adrenal tumors. 6) patients with large thyroid mass or other neck masses precipitating difficult airway. 7) Patients with BMI > 30 kg/m2. 8) Pediatric age group 9) pregnant females 10) C-spine fracture or other cervical disorders with restricted neck movement or unstable cervical spine 11) faciomaxillary injury or anomalies 12) abnormalities of airway like burn contractures and cleft lip/palate,TMJ ankylosis. 13) Unwillingness to give consent

Design outcomes

Primary

Measure	Time frame
In our study we hypothesize that nebulized dexmedetomidine also blunts the intubation response due to its rapid absorption. As dexmeditomidine also causes sedation we also contemplated entropy monitoringTimepoint: premedicatin to 5 min after intubation	—

Secondary

Measure	Time frame
Any adverse effects of the drug Cough, bradycardia, hypotension and sedation.Timepoint: premedicatin to 5 min after intubation	—

Countries

India

Contacts

Public ContactNIMMAGADDA RAJA RATNA KUMAR

NIZAMS INSTITUTE OF MEDICAL SCIENCES HYDERABAD

drshibanipadhy@gmail.com8332921975

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026